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Abstract
Background: Candida represents the most common cause of invasive fungal disease, and candidal blood stream 
infections (CBSI) are prevalent in the ICU. Inappropriate antifungal therapy (IAT) is known to increase a patient's risk for 
death. We hypothesized that in an ICU cohort it would also adversely affect resource utilization.
Methods: We retrospectively identified all patients with candidemia on or before hospital day 14 and requiring an ICU 
stay at Barnes-Jewish Hospital between 2004 and 2007. Hospital length of stay following culture-proven onset of CBSI 
(post-CBSI HLOS) was primary and hospital costs secondary endpoints. IAT was defined as treatment delay of ≥24 
hours from candidemia onset or inadequate dose of antifungal agent active against the pathogen. We developed 
generalized linear models (GLM) to assess independent impact of inappropriate therapy on LOS and costs.
Results: Ninety patients met inclusion criteria. IAT was frequent (88.9%). In the IAT group antifungal delay ≥24 hours 
occurred in 95.0% and inappropriate dosage in 26.3%. Unadjusted hospital mortality was greater among IAT (28.8%) 
than non-IAT (0%) patients, p = 0.059. Both crude post-CBSI HLOS (18.4 ± 17.0 vs. 10.7 ± 9.4, p = 0.062) and total costs 
($66,584 ± $49,120 vs. $33,526 ± $27,244, p = 0.006) were higher in IAT than in non-IAT. In GLMs adjusting for 
confounders IAT-attributable excess post-CBSI HLOS was 7.7 days (95% CI 0.6-13.5) and attributable total costs were 
$13,398 (95% CI $1,060-$26,736).
Conclusions: IAT of CBSI, such as delays and incorrect dosing, occurs commonly. In addition to its adverse impact on 
clinical outcomes, IAT results in substantial prolongation of hospital LOS and increase in hospital costs. Efforts to 
enhance rates of appropriate therapy for candidemia may improve resource use.
Background
Candida sp. is the most frequent cause of invasive fungal
disease in hospitalized patients [1]. The annual incidence
of hospitalizations in the US associated with candidal
blood stream infections (BSI) has risen by 50% between
2000 and 2005 [2]. In addition, Candida now accounts for
12% of all hospital-acquired BSIs [3]. Concurrent with
this absolute growth in the burden of candidemia, health-
care institutions have also witnessed an increase in the
proportion of infections caused by azole-resistant Can-
dida  species, such as C. glabrata and  C. krusei [4,5].
These microbiologic shifts have challenged clinicians'
ability to predict the spectrum of necessary coverage in
an empiric regimen aimed at a suspected Candida infec-
tion.
At the same time, a growing body of evidence points to
an association between inappropriate early selection of
an antifungal agent and worsened clinical outcomes [6-8].
Most studies indicate that failing to administer appropri-
ate coverage, defined as a drug that is in vitro active
against the culprit pathogen, within 24 hours of infection
onset, independently raises the patient's probability of
death by a factor of two or more.
There is therefore little doubt that early recognition and
knowledge of local patterns of candidal resistance can aid
efforts to select appropriate coverage, which in turn
should improve clinical outcomes. What is unclear is the
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impact of inappropriate therapy on economic parame-
ters, namely length (LOS) and costs of hospitalizations.
While on the one hand, the LOS may be reduced due to
an early mortality associated with inappropriate and/or
delayed therapy, it is also possible that such therapy may
actually prolong the LOS, and thus the costs, of a hospi-
talization before resulting in death. We hypothesized that
the latter is the case, and conducted a study to examine
this hypothesis.
Methods
We conducted a retrospective single-center cohort study
at the Barnes-Jewish Hospital (BJH), St. Louis, MO. The
Washington University School of Medicine Human Stud-
ies Committee approved the study, and informed consent
was waved. BJH is a large (1,200 beds) urban academic
medical center serving an inner-city population. Given
that the majority of candidemia patients are found in the
ICU, we included all patients with culture-proven candi-
demia occurring on or before hospital day 14 and requir-
ing an ICU stay between January 1, 2004 and December
31, 2007. At the BJH certain BMT and solid organ trans-
plant patients receive antifungal prophylaxis, with the
duration and agent dependent on how far out they are
f r o m  t r a n s p l a n t  a n d  w h a t  o r g a n  o r  t y p e  o f  s t e m  c e l l
donor they have. Overall, however, for standard ICU
patients, antifungal prophylaxis is not provided. Empiric
coverage is not standardized. For those patients at high
risk for fungemia, antifungal therapy is initiated with
broad-spectrum antifungal therapy at the onset of signs
and symptoms of infection. Those with a lower risk for
fungemia are not started on therapy until they remain
febrile for 2-3 days following empiric antibacterial cover-
age.
Hospital LOS following culture-proven onset of CBSI
(post-CBSI HLOS) served as the primary end-point, with
hospital costs representing the secondary endpoint. Inap-
propriate empiric therapy was defined as 1). treatment
delay of ≥24 hours from candidemia onset with an anti-
fungal agent active against the pathogen or 2). an inade-
quate dose of antifungal agent active against the
pathogen. Adequacy of the dose was based on the dos-
ages recommended by the Infectious Diseases Society of
America and the individual antifungal package insert.
The initial adequate dosage of fluconazole for susceptible
isolates was defined as 6 mg/kg/day for Candida albicans,
Candida tropicalis, and Candida parapsilosis in the face
of normal renal function, and 3 mg/kg/day if creatinine
clearance was < 50 ml/min. Fluconazole was not consid-
ered to be adequate at any dosage for Candida krusei or
Candida glabrata. Total hospital costs (US$) represent
the sum of costs across all individual hospital cost cen-
ters. These cost centers included room and board, phar-
macy, radiology, and laboratory.
We performed descriptive statistics on demographic
and clinical characteristics and outcomes, comparing
those patients getting appropriate vs. inappropriate treat-
ment. To assess the independent impact of inappropriate
therapy on LOS and costs, we developed generalized lin-
ear models (GLM) using a gamma distribution for both
the LOS and costs in order to compensate for their non-
parametric distributions. Although only total costs were
available rather than costs incurred following the devel-
opment of the index infection, we arrived at CBSI attrib-
utable costs by adjusting for the HLOS prior to the CBSI
onset. Statistical significance was set at the p ≤ 0.05.
All analyses were performed in Stata version 9.2 (Stata-
corp, College Station, TX).
Results
Of the 135 ICU patients with candidemia within the
specified time frame, 90 developed it within 14 days of
hospital admission, 80 (88.9%) of whom received inap-
propriate treatment. There was no difference between the
two groups based on age, gender, type and burden of
comorbidities, or the severity of their acute illness (Table
1). Those patients receiving appropriate treatment were,
however, more likely than the inappropriately treated
group to be on a medial service (100% vs. 62.5%, p <
0.001), and to have a CBSI on admission (100% vs. 22.5%,
p = 0.027).
Microbiologically, there were no differences between
the appropriately and inappropriately treated groups. In
both the majority infections were due to Candida albi-
cans (Table 2). The majority of patients were treated with
empiric fluconazole, reflecting the approximately 80%
fluconazole susceptibility among the isolates (Table 2).
Among patients receiving inappropriate therapy, 95% was
deemed inappropriate due to ≥24-hour delay in therapy,
and in 26% this was due to an inadequate fluconazole
dose.
Unadjusted outcomes differed significantly between
the two groups. The median hospital LOS was 13 days
longer and the median hospital costs were nearly double
in the group receiving inappropriate compared to appro-
priate treatment (Table 3). The differences in both crude
hospital mortality (29% vs. 0%, p = 0.062) and post CBSI-
onset LOS (13 vs. 8 days, p = 0.059) also favored appro-
priate therapy, though neither reached statistical signifi-
cance at the p ≤ 0.05. In the adjusted analyses,
inappropriate therapy for CBSI was associated with an
incremental increase in the hospital LOS following CBSI
onset of 7.7 days (95% confidence interval 0.6 to 13.5, p =
0.015) and an excess in hospital costs of $13,398 (95%
confidence interval $1,060 to $26,736, p = 0.033) (Table
4).Zilberberg et al. BMC Infectious Diseases 2010, 10:150
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Discussion
We have demonstrated that among ICU patients with
CBSI onset within 14 days of admission, inappropriate
therapy for CBSI is independently associated with an
incremental increase of 8 days hospital LOS and excess
hospital costs of over $13,000. In conjunction with previ-
ously reported data indicating that inappropriate therapy
increases mortality, we confirm the compelling need for
physicians to maintain a high index of suspicion for CBSI.
Given that over 90% of the patients did not receive appro-
priate therapy, and the bulk of this was explained by a
≥24-hour delay in initiation of treatment, measures
aimed at fostering earlier treatment along with education
Table 1: Baseline characteristics of ICU patients with Candida BSI
Inappropriate (n = 80) Appropriate (n = 10) P value*
Age 57.2 ± 16.5 55.1 ± 21.8 0.774
Gender (Female) 38 (47.5%) 6 (60.0%) 0.518
Race (African American) 22 (27.5%) 4 (40.0%) 0.466
Medical service 50 (62.5%) 10 (100%) 0.027
CBSI on admission 18 (22.5%) 10 (100%) <0.001
Comorbidities
CHF 18 (22.5%) 3 (30.0%) 0.693
CAD 19 (23.8%) 4 (40.0%) 0.270
DM 25 (31.3%) 4 (40.0%) 0.721
COPD 16 (20.0%) 1 (10.0%) 0.680
Liver disease 4 (5.0%) 0 1.000
ESRD 7 (8.8%) 2 (20.0%) 0.261
HIV 1 (1.3%) 0 1.000
Cancer 23 (28.8%) 2 (20.0%) 0.720
Organ transplant 1 (1.3%) 1 (10.0%) 0.218
APACHE II score 16.3 ± 6.7 16.3 ± 7.8 0.990
MV 52 (65.0%) 6 (60.0%) 0.739
Pressors 23 (28.8%) 4 (40.0%) 0.479
CVC present 70 (87.5%) 8 (80.0%) 0.617
*P values derived using Student's t-test for continuous and Fisher's exact test for categorical variablesZilberberg et al. BMC Infectious Diseases 2010, 10:150
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regarding the correct dosing of azoles may improve both
clinical and economic outcomes.
Consistent with current epidemiologic data, C. albicans
in our cohort was responsible for about 2/3 of all CBSI
[4,5]. At the same time, the prevalence of azole resistant
organisms was approximately 20%. Nevertheless, the vast
majority of reasons for therapy being deemed inappropri-
ate was not the selection of the wrong anti-fungal agent,
but, rather, its delayed administration. This suggests that
just by having a high index of suspicion for CBSI and
instituting anti-fungal therapy while awaiting culture
confirmation, 80% of the cases may be moved into the
appropriate care category, and thus given the opportunity
for better potential outcomes.
Historically, CBSI has been a syndrome with mortality
in the range of 40%, and consequently, much work has
focused on how to improve this outcome. Three studies
have documented that prompt appropriate antifungal
treatment independently decreases the risk for mortality.
Morrell and coworkers demonstrated that a delay in
treatment is frequent and one of as little as 12 hours from
obtaining culture is independently associated with a 2-
fold increase in the risk of hospital death [6]. Garey and
coworkers confirmed these observations in a multicenter
Table 2: Microbiology and treatment parameters
Inappropriate (n = 80) Appropriate (n = 10) P value
Microbiology*
C. albicans 53 (66.3%) 5 (50.0%) 0.319
C. glabrata 13 (16.3%) 2 (20.0%) 0.671
C. parapsillosis 8 (10.0%) 2 (20.0%) 0.307
C. tropicalis 4 (5.0%) 1 (10.0%) 0.453
C. kruzei 2 (2.5%) 0 1.000
C. lucitaniae 1 (1.3%) 0 1.000
Fluconazole susceptible 63 (78.8%) 8 (80.0%) 1.000
Antifungal treatment¶
Fluconazole 42 (52.5%) 6 (60.0%) 1.000
Caspofungin 35 (43.8%) 4 (40.0%)
Amphotericin B 2 (2.5%) 0
Voriconazole 1 (1.3%) 0
Antifungal delayed 24+ hours 76 (95.0%) 0 <0.001
Inappropriate dose 21 (26.3%) 0 0.109
CVC removed 58 (82.9%) 6 (75.0%) 0.629
All p values are derived via Fisher's exact test
*Total number adds up to over 100% due to overlap in pathogens detected
¶Does not add up to 100% due to roundingZilberberg et al. BMC Infectious Diseases 2010, 10:150
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cohort, where they documented increasing mortality
based on the delay, measured in days from when the cul-
ture was drawn to antifungal treatment [7]. Similarly, a
recent study by Labelle and colleagues expanded the defi-
nition of inappropriate therapy for fungemia to encom-
pass both delay of treatment and inadequate dosing of
fluconazole [8]. Inappropriate therapy thus defined raised
the risk of death 9-fold. All three of these studies under-
score the importance of prompt appropriate treatment of
candidemia in order to impact survival.
In addition to being deadly, candidal BSI remains a
costly disease, with the cost of care ranging from $15,000-
$40,000 per case [9-11]. In one report, the excess costs of
care for candidemia were more than $15,000 over the
costs related to treating BSIs due to bacterial pathogens
[9]. Driving these greater costs was an accompanying 5-
day excess length of stay in the setting of candidemia. Our
study builds on these observations and extends them to
quantify excess LOS and costs associated with inappro-
priate treatment of BSI, calling into question whether
more prompt identification and treatment of CBSI might
not only improve survival, but also reduce expenses. A
major obstacle to this in clinical practice remains the lack
of adequately validated and sufficiently specific predictive
tools to determine the likelihood of CBSI in a critically ill
patient with multiple risk factors [12-14]. Therefore,
much is left to clinical judgment, particularly in terms of
evaluating the balance between an individual patient's
Table 3: Unadjusted Outcomes
Inappropriate (n = 80) Appropriate (n = 10) P value*
ICU LOS (days)
Mean ± SD 10.8 ± 10.8 9.1 ± 10.1
Median (IQR 25, 75) 8 (4, 14) 4 (2, 14) 0.371
Hospital LOS (days)
Mean ± SD 24.4 ± 17.5 10.7 ± 9.4
Median (IQR 25, 75) 21 (13, 28) 8 (3, 16) 0.002
ICU cost ($)
Mean ± SD $13,448 ± $14,872 $12,801 ± $14,324
Median (IQR 25, 75) $10,249 ($4,290, $18,757) $5,545 ($2,750, $19,250) 0.559
Hospital cost ($)
Mean ± SD $66,584 ± $49,120 $33,526 ± $27,244
Median (IQR 25, 75) $52,437 ($35,977, $81,233) $26,916 ($11,388, $46,454) 0.006
Hospital LOS (days) following onset of CBSI
Mean ± SD 18.4 ± 17.0 10.7 ± 9.4
Median (IQR 25, 75) 13 (8, 22) 8 (3, 16) 0.062
Hospital mortality 23 (28.8%) 0 0.059
*Derived using Mann Whitney U test for continuous variables and Fisher's exact test for categorical variableZilberberg et al. BMC Infectious Diseases 2010, 10:150
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risk for CBSI and the overall risk for developing resis-
tance to anti-fungal agents due to their overuse.
Our observations echo those reported in other syn-
dromes. For example, Shorr and colleagues evaluated the
economic implications of instituting an early goal-
directed therapy protocol in the emergency department
o f  a n  u r b a n  t e r t i a r y  c a r e  h o s p i t a l  [ 1 5 ] .  I n  t h i s  s t u d y ,
appropriate treatment was associated not only with
reduced mortality [16], but also with a reduced LOS and
hospital costs. Similarly, the same group reported that
inappropriate treatment of methicillin-resistant Staphy-
lococcus aureus (MRSA) sterile site infections was associ-
ated with a prolongation of hospital LOS and an increase
in costs [17].
Our study is subject to a number of limitations. Its ret-
rospective design may have predisposed it to a selection
bias. We attempted to mitigate this by enrolling consecu-
tive patients meeting the pre-specified enrollment crite-
ria. Although confounding is a potential problem with all
cohort studies, we adjusted our analyses for potential
covariates. Nevertheless, the possibility of residual con-
founding persists. The study's single center nature may
limit the results' generalizability to centers similar to
ours.
Despite these limitations, to the best of our knowledge,
this is the first study to quantify the potential excess costs
related to inappropriate treatment of CBSI. Together with
the evidence for improved survival with appropriate
treatment and the low prevalence of such, our results sug-
gest a need for a more balanced approach to CBSI identi-
fication and treatment. Not only is there a need to
heighten clinical suspicion among appropriate patient
populations, but there is a clear need for rapid bedside
tools to identify this infection, so as to commence prompt
therapy. Given the lack of success developing a prediction
model, clinical judgment could be aided greatly by a rapid
bedside assay, such as β-D-glucan, though this has not
been validated among the critically ill [18,19].
Conclusions
In summary, the current data shed light on the potential
cost and hospital resource savings that may be possible if
CBSI were to be treated promptly and appropriately. This
information, in conjunction with the life-saving potential
of such a strategy, makes a compelling argument for
improving processes around identification and treatment
of this syndrome in critically ill patients.
Key messages
• Inappropriate treatment of candidemia in the ICU is
frequent.
• Having a high index of suspicion for CBSI and insti-
tuting anti-fungal therapy while awaiting culture con-
firmation may result in moving 80% of the cases from
the inappropriate into appropriate care category.
• Inappropriate therapy for CBSI is independently
associated with a significant increase in hospital
resource utilization.
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